With that, it's all yours, Pete. Great. Jim, thank you. I've known Jim for a very long time, and welcome. I appreciate everybody's interest in Zomedica Corp. We are listed on the NYSE American under the ticker ZOM. No need to read it all in entirety. If you can, it's listed on the website, but essentially, it's our forward-looking statements and disclosures, which I encourage everybody to read. Our 10-K, which was filed in April, and we had a 10-Q that was filed shortly thereafter in May. You know, what is Zomedica? We are a veterinary animal health company, right? We're playing in a really big space. Most of our executive team came from human health. So we're all doing this, some of us for the first or second time in animal health, and it's a novel business in that we don't necessarily have to deal with FDA, and it's primarily a cash pay business. So some of the things that we had to worry about in human health, those obstacles are removed and still very large unmet needs in these markets. So what do we do? We are a diagnostic and therapeutic company, as I said, for the veterinary or animal health space that we focus on the five pillars, and you'll hear me say that repeatedly. And what are the five pillars? The five pillars are we want a better outcome for the animal, specifically some novel treatments in the animal gets better or unique care. Secondly, the pet parent, and you notice we call them pet parents and not owners. We want the pet parents to definitely believe that they are getting better care for their animal and they're willing to pay for it. Lastly, our primary focus is on our veterinarian customer, and we want to make their life easier. Their practices are under a lot of duress, and we'll talk about that in a moment. We want to make them more efficient. We want to not take a lot of their cash with upfront investments. And at the end of the day, do they get a better outcome and make the same or more money? So that's what we're trying to do. Everything we do is grounded in that mission. Lots of numbers on a page here. What's noteworthy is the veterinary services market is $62 billion. You know, I've seen a range as low as $50 billion and as high as $100 billion. So, you know, I think there's a lot of controversy. The takeaway, it's just a really large market. What's important to me, and I joined the company about a year and a half ago. This management team is about three years in the making. I've been there for about half of it, a year and a half now. But these trends all started during the pandemic back in 2020. There's more pet ownership each and every day. In fact, 23 million dogs and cats were added to households during the pandemic. Younger generations, and I have a bunch of 20-year-old kids myself, they are forgoing marriage, and a lot of them giving birth to children, and instead are adopting pets. And many of them, about half are even doing more than one pet, and they treat them as I did years ago as a baby, right? So there's an increased sense of treating these animals, and there's more of them like a child or part of the family. What's also interesting and not listed on here, so those are all positive trends for our business. The other trends that aren't listed are the kind of headwinds for the vets that are tailwinds for our company. Specifically, there's fewer vets out there. They're retiring. They're being consolidated. The help they used to get for $8, $9, $10 an hour in the form of veterinary techs has gone away, right? There was a labor shortage, and the labor that's out there is demanding $15 or $20, and they can get that working at Subway or McDonald's, right? So it's pretty frustrating for the vet community, but our products are designed to take some of that frustration out. The other thing that vets had, and people that are my age remember, to get the fancy food or the fancy collars, a lot of times you bought them at the vet. Those days are gone. You can have food delivered from Chewy, probably same day, right, or on Amazon. So a lot of the high-margin items that help the vets, you know, pay the bills and keep the lights on are no longer there. So the overall trend here or takeaway, big market with very positive trends, you know, for our business. And just some things here, and we'll get into it. Again, we have addressable market that's over $2 billion. We currently have five product platforms across two operating segments. The business last year grew 33%. We had 69% margins. So we have industry-leading top-line growth in margins, and we'll talk about some of the financials here in a moment. So what do we do? The easiest way, and we could talk for hours really, and we don't have hours today, we can talk for hours about our products. What we have, though, are two operating segments. We have therapeutic devices on the left. Historically, that was almost all of the sales for the company. These you could think of as organic because most of these have been with us well over a year, some in the case of PulseVet, nearly two. PulseVet to the left is a capital purchase sold directly through our direct sales force and our distribution partners. You can see it's a large unit or reasonably large unit, but certainly space-worthy for the practice. When we bought PulseVet, which was back at the end of 2021, it was a leader in equine. It had over 1,100 of these instruments placed. The corded product that you see attached to it is an X-Trode. Why is that important? That's a consumable stream. About 60% or more of PulseVet's revenue comes from the repurchase of these, once they wear out, X-Trodes. This is a shockwave therapy used to provide therapy to horses, i.e., ligament damage. You know, the equestrian team, a lot of the Thoroughbred racers use them as well. A leader, as I said, in the equine market. When Larry and the management team took over, they redesigned the X-Trode. The X-Trode was too big and too powerful for dogs and cats. So the first order of business was to design an X-Trode where the dog and cat didn't have to be put asleep, you know, during the procedure. And that's been game-changing for us. So the drivers in this business are to continue to drive utilization in the equine business. Of course, new applications, and I encourage you to look at some of the science behind it in the equine space, but we're really bullish on getting these instruments into the small animal market. And again, that's sold directly through, primarily directly through our sales force, which is about 38 territories in the U.S. today. Assisi is a little bit of a nuanced product. This is our only product sold through retail, and it's almost exclusively with Amazon and Chewy. If you Google on your phone, you can see that these are devices that do have, they last about a year. So about 2 out of 3 or more of these customers will come back and purchase another one. It's a device that you put on the animal to either reduce pain. I use it on my animals for anxiety reduction, particularly during fireworks time. So PulseVet and Assisi have historically made up 90% or more of the sales of the company, and we'll dissect that a little further. And in our filings, we do disclose, you know, with more granularity what those numbers are. To the right is the exciting stuff. This is the new products. None of these really have seen store sales. You know, moving left to right, you see TRUFORMA. That's been around a while. So we give that box away. Down at the bottom, cartridges go into that, and we have different applications, whether it's GI applications for dogs or cats, ortisol for dogs. We had a bunch of new assays for horses last year. These range in price from, call it $35, $37, upwards of $100, one-time use products. So it is a true razor and razor blade model. And we've publicly announced that we're going to launch five new ones this calendar year, 2024. So you'll be seeing lots of news around that. The middle product, which was launched in the second half of last year in a limited commercial release, is another instrument that we place, i.e., we don't sell. It is a microscope. So every vet has a microscope. Some like using them more than others. But essentially, this is auto slide preparation. So remember what I just talked about is we want to get better outcomes, but we also want to make folks more efficient. So we're selling, we're giving the device, placing the device, and then selling the recurring service, which ranges from $500-$1,000 a month. We also offer pathology rates. So it is a service-oriented business. We're in the early innings, right? It was launched last year, and we tweaked the product. We've said very publicly we're trying to add AI to this product. That will probably be the biggest catalyst to really get this product jump-started. And the product out to the right, we're probably most bullish on in the diagnostic segment, and that's VetGuardian. We started selling VetGuardian in the early part of 2023, but really in earnest in the back half of the year. Why? Because we did an acquisition of Structured Monitoring Products and bought all the rights to this product. It is a slick product. It is a product that is attached to the cage in the animals. Diagnostics are read wirelessly. So think of the dogs that wear the cone on their head or wires. They tend to not like that or tear it off. If your pet dies at the veterinary clinic, about three quarters of the time it's post-operatively, kind of behind the curtain in the cage because they're manually looking at the animal overnight or not at all. So that's the problem that we're solving for. We had a big first quarter. We also announced in the first quarter that we're seeing a lot of upside, not only in the service that we start in service contracts that are kicking in this year, but more importantly, customers that are buying second, third, and in the case of a couple other customers, you know, 8, you know, 1 customer bought 8. And I think Larry said on the last call about a quarter or more of these customers are buying more than one right out of the chute. So really exciting times on the diagnostic side of the business. As I said, a little bit of a wild card, lots of shots on goal for us from that. The therapeutics devices are a little bit more predictable. So how are we doing financially? You know, this, you know, is a true up and to the right story. The business raised $250 million during the pandemic, the previous management team. However, they didn't have any sales, as you can see out to the left. Larry joined the company to put that money to work. After the previous team couldn't quite get going, Larry delivered $4 million in his first year, which was primarily PulseVet, which we talked about. Then he took that business to nearly $19 million on the year-end in 2022. That's when he reached out to me to help join the company, you know, finalize, get the growth really going, and start talking to investors like we're having conversations today, as I've been in public company settings for most of my senior career. We announced in January, and then we finalized the number April 1st, $25.2 million for the year-ended 2024. So that's about a 32%-33% growth rate, all while delivering 69%, 69% margins. Our operating cash burn fell to about under $11 million for the full year, which translates into less than $3 million of operating burn, just an operating burn per quarter. We ended the year with over $100 million and nearly $91 million in Q1. So you can see that we are truly a high-growth, high-margin business that's approaching profitability. Some other things that are noteworthy, it is seasonal, right? And some folks take some getting used to. I've been in human medical devices that this resembles that. What that means is Q1 is typically soft. We see an uptick from Q1 usually into Q2 and Q3, and that could go either way on which quarter is bigger. In our case, Q3 is generally a little bigger. And then Q4, it's blown out of the park. One, because there's a capital component. But two, our business, unlike human health, is driven by trade shows. And a lot of veterinary shows happen the back half of the year, especially as you get into October and November. And unlike human health, where you can't buy the device, vets bring their checkbooks. They also have visibility on how they're doing for the year. They have the ability potentially to take an extra tax credit. So we see a big uptick in Q4 and then a seasonally adjusted step down a little bit in Q1. But you can see we still delivered nearly $6.3 million when we reported back in early May the numbers. So pretty significant growth trajectory here. We're really proud of that. Also, what we did, so in addition to reporting those results, we were really excited for the first time in company history. I believe it was around January 17th, we had revenue guidance. And we gave a lot of guidance, but we gave the highlight was revenue guidance. And we guided, I did, $31-$35 million. I was just talking to Jim before we got started here. Not too many management teams, you know, sign up for 23%-39% growth two weeks into January. So that's what this management team did. And I'll go a little deeper on why we feel so good about that guidance here in a moment. And you can see the quarterly revenue, which I just talked about, and we reported $7.3 million. It was our highest revenue quarter ever. That was Q4. And then we had our highest ever Q1, which was $6.3 million. So really good news there. Gross margins have historically been approaching 70%. The particular guidance for this year was 65%-70%. And the reason being, we did some acquisitions that we need to grow into get some of the growing pains. But we were pleased to report that we were still north of 66% in Q1, you know, well within our range. Then if you take out the impact of those acquisitions, we were just a little under 70%, 69% and some change. So gross margins are predictable. We expect them to start with a 7, certainly later in the year or early next year, and then go up from there. And very atypical, right? Our company has $91 million in the bank. So we are not a company that needs to go out and raise money. We have no debt. So we're not going to take on any debt here. So overall, good story. I also, you know, gave some investors a picture into how much we thought we would burn this year. We said the operating cash burn would be in the $12 million-$18 million range, including capital and some investments that we have on our electronic platforms. So we'll still continue to burn money this year and 2024. But what I said, what Larry has said publicly is we expect our first cash flow positive months to occur in the back end of 2025. So we are measured in days or quarters versus years till we get to profitability. And we don't, we do not believe that the cash will ever fall below $65 million. And I actually gave a range of $65-$75 million. There were some investors that were nervous that we may have to go out and raise additional money. And what we said is we don't believe we'll have to do that because the low watermark of cash, which occurs about a year from now, give or take, is $65-$75 million. So overall, you know, a really good financial picture and a company that's, you know, been pretty transparent on setting targets and then having folks measure those targets. So as I just promised a moment or two ago, you know, how do we feel good about guidance, right? So we said $31-$35 million, 23%-39% growth rate. So as I think about, or as I instructed people, the $31 million comes, and I talked a few moments ago about therapeutics. Those products have been with us, you know, up to two years, a very predictable model. So as I think about the bottom end of this range, whether it's all the way to $31 million or whether it's $28, $29, or $30 million, that will come from those two products that I spent time talking about about 10 minutes ago. So we feel pretty good about that. We should be able to get to the bottom of the range. And then the diagnostics get us either to $31 and then beyond, right? So those are the wild cards that I spent time talking about. What are the drivers? What are the incremental drivers that get us not only to the $31, but get us to the $35, and more importantly, get us beyond the $35? As we said, we got to approach $50 million annual run rate to become profitable, which we expect to be there late next year. But how are we going to get there, right? You know, the PulseVet product line. So we need to continue to penetrate the equine market. We see utilization trends from the recurring revenue increasing. We also have a number of initiatives on new applications in the equine market and internationally through distribution. We had some announcements around that that came out not too long ago. The biggest driver will be placing more PulseVet systems into small animal practices. I'm a German Shepherd lover and owner. It's been game-changing for my German Shepherd using the PulseVet product on her aging hips, which is a problem for working dogs. I encourage you all, we had, albeit a small n, but a really intriguing clinical study around working dogs, particularly with the armed forces and law enforcement agencies. We're going to continue to drive growth with PulseVet in particular, and perhaps some new applications in international markets for the Assisi product line. We're just going to keep pounding away on therapeutics and then diagnostics. TRUFORMA. We have new products left, right, and center. We have about a dozen or more assays today. That number grows to 16 or 17 here in the coming months. And those will really leverage an acquisition that we did late last year, which was Qorvo Biotechnologies. So encourage you all to read some of the, you know, I guess, rationale and justification for it. But TRUFORMA is one that I'm personally bullish on. TRUVIEW, we're getting the growing pains behind us. As I said, the key to growing TRUVIEW is getting those placements out there. And we have some slick technology coming from AI that we've committed to that I believe will help that product and take us from kind of a limited commercial launch into a full-on commercial launch. And then lastly, the VetGuardian. And I talked extensively a few minutes ago about that. These are the hang them on the cage. I know personally, if my animals were staying post-operatively, I'd want a VetGuardian hooked up to it, you know, good visuals in, you know, 24/7 monitor. As I said, there's a service component to all of these. Roughly two-thirds of our revenue comes from recurring sources. So it's a pretty slick model. And as you all are aware, you know, generally consumables carry a higher margin. That's why we feel really good about committing to 65%-70%. And then, as I always say, start with a 7 later in life. So the takeaway here is $31 million-$35 million and then get us closer to $50 million. And once we get closer to $50 million, that's when profitability kicks in. So, you know, all reasons I joined the company, not having to go out and raise money and just, you know, really become an execution story, building a productivity model and then building out a commercial team, which we've done. We're almost at full strength now. We have 38 territories. And we brought in Kevin Kloes, who is a star at Heska. Many of you know the Heska story. Kevin was so excited about our products here that he joined our company last November. And he's built out his team. So all good news for the business. And as I said, we reiterated this guidance back just a few weeks back. So where does that leave us? You know, before I turn it over to Q&A, it's a big market opportunity. These are unmet needs for animals and helps the veterinary community. We're innovative. You know, we're still nimble. We're a small company that's still innovating with great R&D efforts. As I said, we feel really good about our commercial channel, not only domestically with Kevin at the helm, a lot of the distribution agreements. We had a lot of public announcements a year or so ago on that, as well as we sell through Amazon and Chewy. We have really good channels, a multi-channel approach. The portfolio will continue to expand. We've done a lot of M&A. However, the numbers that I put out there, whether it's $31-$35, whether it's $50 or even $100 million, we can get there with the products we have today. But we do have a lot of deal flow. We have a gentleman named Greg Blair, who has the most animal experience in our leadership team. He sees probably one or two deals a day. Literally, probably 2 or 3 of them make it all the way into diligence or some form of confidentiality that makes it to my desk or Larry's desk. So we have plenty of M&A opportunities that could potentially drive growth faster than the numbers that I just talked about, you know, over the course of the last 20 minutes or so. We continue to have operating efficiencies. Our headquarters are in Ann Arbor, Michigan. But our primary operating site is just outside of Atlanta. And our R&D capabilities and the TRUFORMA products are based outside of the Twin Cities in Minneapolis, Saint Paul. We're self-funded. We don't have any debt, no need to take on any debt or raise any money, and reported $90.9 million or just under $91 million in cash, cash equivalents, and available for sale securities at Q1. So with that, Jim, I hope it's a good overview for the audience. I'll turn it over to Q&A. Great. Thank you, Pete. You know, I covered Heska before they got acquired. I covered Abaxis before that got acquired. I covered IDEXX and VCA. So, you know, we know the vet industry is a profitable industry. You know, can you talk about your diagnostic product, TRUFORMA, or how it compares to the ones out there? And, you know, are there blood tests that you can do that the other ones don't? Yeah. So that's primarily it, Jim. So first off, we're generally not competing, right? We are not kind of, we are not a wellness where you take your German Shepherd once a year. These are for your presenting, you know, in the case of GI disorder, take that one. That's either the most common or certainly top two or three, your dog that has diarrhea, it's vomiting, your cat, right? So these are the types of tests that help that are different than the current offerings that are not part of an annual checkup, right, which make our business a little bit more unique. And what's even more unique, Jim, is its point of care. So these results are either real-time or within a couple of hours. And the vet can start taking the healing home with the animal. It doesn't have to go out to a reference lab. Now, admittedly, reference labs are getting faster, but it sure would be nice to get the results, you know, real-time versus waiting two or three days, and the treatment could start earlier. So to answer your question, yeah, our products are different, very different than the big boys are offering. And in many cases, they're complementary. So you could see a TRUFORMA next to, you know, an Abaxis or a Heska system as opposed to instead of. Yes, we can. And we do. All right. And, you know, one of the, especially with Abaxis, you know, there was a lot of synergies with the pharmaceutical companies that were selling the treatments for the conditions. I mean, have you considered partnerships with, you know, vet pharmaceutical companies to, you know, promote the products? Yeah. So we do. We consider, we're a very forward-looking company. You know, Larry came from U.S. Surgical, so he was part of the acquiring conquering partner that became, you know, Tyco, right, the giant. Larry was there forever. Many of our management team, including myself, have been in that type of environment. So we do consider not only that partnership, but all kinds of partnerships. Now, we're unlikely, never say never, but very unlikely to go into pharmaceuticals ourselves, but to partner or pair for sure. I'll take it even a step further. We've said this publicly, Jim, you know, that when we acquired the Qorvo business in December or late last year, we acquired the human health rights, right? So we are not going to do that ourselves. But there was a lot of work done when we acquired the rights, you know, for the animal rights. We also got the human health element. So there's some nuances there where we won't go, definitely will not go it alone, but we could partner on the human health side as well, which is not part of any of our projections that would be pure upside. Qorvo, they were the manufacturer for TRUFORMA? They were. Also the R&D, you know, the partner R&D partners. So what we said, in addition to probably financially this being savings for us in the long run, we were able to not only take control of the entire supply chain, we're also accelerating the R&D pipeline. That's the exciting part. And Larry was quick to point out that we're going to launch 5 or more assays this year, right? So as I said, we had pretty aggressive guidance back in January, and you should start to see a steady diet of new assays coming. And if you go back, you'll see some slick ones that were introduced last year as well. And one that I'm really excited about is for Cushing's disease in horses. If you can get on that early, that there's almost no, one of your earlier questions is this is really differentiating technology, right? This allows vets to test the stable- side, right, with their horses for Cushing's disease. And I'm happy to go deeper with anyone that wants to talk to me one-on-one about it, but that'll be a key growth driver within the TRUFORMA arsenal. And you think the consumables for those products will be, you know, margins for those consumables will be north of 70% as well? Yeah, 100%. Yes. Yeah. And in fact, what we're doing, Jim, and again, in the interest of time, won't go deeper, we're putting two assays in one cartridge, right, which a little bit of a price break for the vet, but even enhances the margins. And now we have complete control. So we're not paying any royalties or any kind of supplier markups because we're doing it ourselves in Minneapolis. So, you know, you're not the normal penny stock company that's out there. You've got a good balance sheet. You've got very good revenue growth. You've got a path towards profitability. You know, what do you think will be the major catalysts, you know, for people to understand the value of Zomedica? Yeah, I think just to evaluate the business, right? You know, get comfortable that it's a big market. Get comfortable that we have unique products, offerings within that. And then, you know, get comfortable that therapeutics is going to continue to grow. It's very predictable. So you're really betting, in my opinion, Jim, on the diagnostics business and betting on this management team to continue to execute, you know, to be able to build a salesforce and a model. So I think at this stage, we've de-risked the business a lot. And you've known me for a long time. I probably wouldn't be sitting here if I didn't believe that this business was kind of a, I don't want to call it plug and play because we're such a little guy in the space. But it really is an execution story for us right now. And then, you know, it's really exciting because we have a number of shots on goal, so to speak, on the diagnostic side. So I'd want investors to kind of think about, you know, if you think about us right now, we're almost, we're trading at like 1x, right? When you cash back. So it's an intriguing entry point for folks that can invest in stocks, you know, that are under $1. Got it. Got it. All right. Well, we are out of time, but I just want to say thank you again for presenting today. And hopefully you come back again soon. We get an update. We appreciate it. Thanks, everybody, for attending. Thank you, Jim. Bye-bye. Bye-bye.